Ann Lucena Net Worth

The estimated Net Worth of Ann Lucena is at least $148 Tausend dollars as of 22 August 2023. Ann Lucena owns over 7,500 units of Cerus stock worth over $148,182 and over the last 3 years Ann sold CERS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ann Lucena CERS stock SEC Form 4 insiders trading

Ann has made over 1 trades of the Cerus stock since 2023, according to the Form 4 filled with the SEC. Most recently Ann bought 7,500 units of CERS stock worth $12,675 on 22 August 2023.

The largest trade Ann's ever made was buying 7,500 units of Cerus stock on 22 August 2023 worth over $12,675. On average, Ann trades about 1,875 units every 0 days since 2021. As of 22 August 2023 Ann still owns at least 72,284 units of Cerus stock.

You can see the complete history of Ann Lucena stock trades at the bottom of the page.

What's Ann Lucena's mailing address?

Ann's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD, CA, 94520.

Insiders trading at Cerus

Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash und Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.

What does Cerus do?

cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.

Complete history of Ann Lucena stock trades at Cerus

Cerus executives and stock owners

Cerus executives and other stock owners filed with the SEC include:

• William Greenman,
  President, Chief Executive Officer, Director
• Vivek Jayaraman,
  Chief Operating Officer, Chief Commercial Officer
• Laurence Corash,
  Chief Scientific Officer
• Richard Benjamin,
  Chief Medical Officer
• Kevin Green,
  Chief Financial Officer, Vice President - Finance
• Carol Moore,
  Senior Vice President - Regulatory Affairs, Quality and Clinical
• Chrystal Menard,
  Chief Legal Officer and General Counsel
• Jami Nachtsheim,
  Independent Director
• Daniel Swisher,
  Independent Chairman of the Board
• Timothy Anderson,
  Independent Director
• Frank Witney,
  Independent Director
• Gail Schulze,
  Independent Director
• Eric Bjerkholt,
  Independent Director
• Timothy Moore,
  Independent Director
• Tim Lee,
  Investor Relations Director
• William J Dawson,
  Chief Financial Officer
• Caspar Jan Hogeboom,
  Managing Director Cerus Europe
• Bruce C Cozadd,
  Director
• David N Cook,
  Vice President, R & D
• Chrystal Jensen,
  Chief Legal Officer
• Stephen T Isaacs,
  Chief Executive Officer
• Gregory W Schafer,
  Chief Financial Officer
• International Inc & Subsidi...,
  10% owner
• C Raymond Jr Larkin,
  Director
• Bj Cassin,
  Director
• Howard G Ervin,
  Vice President, Legal Affairs
• Claes Glassell,
  Executive Officer and Director
• William R Rohn,
  Director
• Dean A. Gregory,
  
• Ann Lucena,
  Director
• Hua Shan,
  Director